Avalo Therapeutics (AVTX) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 2, 2026, and will be held virtually, allowing shareholders to vote and ask questions online.

• Shareholders will vote on electing seven directors, approving an amended employee stock purchase plan, and ratifying the appointment of Ernst & Young LLP as the independent auditor for 2026.

• The record date for voting is April 6, 2026, with 26,714,337 shares outstanding and entitled to vote.

• Proxy materials are available online, and multiple voting methods are provided, including internet, phone, mail, and during the meeting.

Voting matters and shareholder proposals

• Proposals include electing seven directors, approving the Second Amended and Restated 2016 Employee Stock Purchase Plan, and ratifying Ernst & Young LLP as auditor.

• Shareholders may submit proposals for the 2027 meeting by December 11, 2026, or nominate directors between February 2 and March 4, 2027.

• Voting requires a quorum of one-third of outstanding shares; broker non-votes and abstentions are counted for quorum but have no effect on proposal outcomes.

Board of directors and corporate governance

• The board will be reduced from nine to seven members after two directors step down at the 2026 meeting.

• The board is majority independent, with separate roles for chairman and CEO.

• Committees include Audit, Compensation, Nominating and Corporate Governance, and Science and Technology Advisory.

• Corporate governance guidelines and a code of ethics are in place, with policies on insider trading and director independence.